Lilly Seaport Innovation Center (LSC) serves
as the central hub for Lilly's genetic medicines efforts and houses
the first East Coast Lilly Gateway Labs
New 346,000 square foot facility will
accommodate approximately 500 Lilly scientists and researchers, in
addition to 200 people from Lilly Gateway Labs' companies
INDIANAPOLIS, Aug. 13, 2024 /PRNewswire/ -- Eli
Lilly and Company (NYSE: LLY) today announced the opening of the
Lilly Seaport Innovation Center (LSC), a research and development
facility in the Boston Seaport dedicated to advancing Lilly's
efforts in RNA and DNA-based therapies as well as discovering new
drug targets to create life-changing medicines across several
disease states, including diabetes, obesity, cardiovascular
diseases, neurodegeneration and chronic pain.
"The opening of LSC expands upon Lilly's long-standing presence
in the Boston area," said
Daniel Skovronsky, M.D., Ph.D.,
chief scientific officer and president, Lilly Research
Laboratories, president, Lilly Immunology. "We are committed
to being supportive neighbors in this hub of discovery and
innovation, further collaborating with leading institutions
and new talent to continue delivering transformative medicines for
the people who need them most."
LSC occupies 346,000 square feet in a 12-story building,
developed and operated by Alexandria Real Estate Equities, Inc.
(ARE), in the rapidly expanding Seaport district of Boston. The new site includes laboratories and
office space and will also house the first Lilly Gateway Labs
location on the East Coast, fostering a culture of shared expertise
and real-time learning to accelerate the development of novel
medicines. LSC will accommodate approximately 500 Lilly scientists
and researchers, in addition to 200 people from the companies
within Lilly Gateway Labs.
About Lilly Gateway Labs
Lilly Gateway Labs is
a best-in-class innovation hub that connects promising, early-stage
biotechs to the power of Lilly's expertise. By fostering scientific
breakthroughs and helping biotechs remove hurdles, we help
companies speed the development of life-changing medicines for
patients around the world. We apply a one-of-a-kind, hands-on
approach to scientific engagement, offering not just
state-of-the-art wet lab spaces and strong operational support, but
also curating programs to help biotechs avoid common
pitfalls. Our flexible model ensures companies can execute on their
scientific vision while maintaining full ownership of their
intellectual property. Since opening in December 2019, Gateway Labs in San Francisco has hosted over 20 biotech
companies, with more than 50 therapeutics and platforms currently
in development, and more than $1
billion raised by partner companies. In 2024, Gateway Labs
is expanding to four sites across San
Francisco, San Diego, and
this new site in Boston to meet
the needs of emerging biotechs in thriving life science
communities. For more information on Gateway Labs, visit
www.gatewaylabs.lilly.com.
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help tens of millions of people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about Lilly Seaport Innovation Center (LSC) and reflects
Lilly's current beliefs and expectations. However, there can be no
assurance that LSC or the science being conducted there will
achieve Lilly's objectives or that Lilly will execute its strategy
as planned. For further discussion of risks and uncertainties
relevant to Lilly's business that could cause actual results to
differ from Lilly's expectations, see Lilly's Form 10-K and Form
10-Q filings with the United States Securities and Exchange
Commission. Except as required by law, Lilly undertakes no duty to
update forward-looking statements to reflect events after the date
of this release.
Refer to: Stefanie Prodouz;
stefanie.prodouz@lilly.com; +1-317-287-9899 (Media)
Joe Fletcher; jfletcher@lilly.com; +1-317-296-2884
(Investors)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport-302219992.html
SOURCE Eli Lilly and Company